CytomX Therapeutics Q4 2023 GAAP EPS $0.01 Beats $(0.03) Estimate, Sales $26.607M Beat $21.043M Estimate
Portfolio Pulse from Benzinga Newsdesk
CytomX Therapeutics (NASDAQ:CTMX) reported Q4 2023 earnings of $0.01 per share, surpassing the $(0.03) estimate, with sales of $26.607M beating the $21.043M estimate, marking a 2.71K% increase from the previous year.
March 11, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytomX Therapeutics reported a significant Q4 2023 earnings beat with EPS of $0.01 and sales of $26.607M, far exceeding estimates and showing a massive year-over-year growth.
The substantial beat on both earnings per share and sales estimates, coupled with a dramatic year-over-year sales increase, is likely to positively impact investor sentiment and potentially drive up CTMX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100